Skip to main content
. 2021 Jan 28;67:102738. doi: 10.1016/j.scs.2021.102738

Table 4.

Associations between multiple classifications of COVID-19 CFR and mortalities of other diseases.

Covariate CFR Category* Odds Ratio** SE P-value 95 % CI
Lower Upper
Alcohol use disorder HH 1.088 0.061 0.168 0.965 1.227
LL 1.149 0.049 0.005 1.044 1.266
Asthma HH 4.584 0.293 <0.001 2.583 8.137
LL 0.818 0.293 0.492 0.461 1.452
Atrial fibrillation HH 1.324 0.081 0.001 1.130 1.551
LL 0.992 0.066 0.902 0.872 1.128
Cardiomyopathy & myocarditis HH 1.233 0.052 <0.001 1.113 1.366
LL 1.130 0.050 0.014 1.024 1.246
Cardiovascular HH 0.817 0.038 <0.001 0.759 0.880
LL 0.949 0.036 0.142 0.884 1.018
Cerebrovascular HH 1.267 0.041 <0.001 1.169 1.374
LL 1.053 0.038 0.180 0.977 1.135
COPD HH 0.996 0.010 0.705 0.976 1.016
LL 1.028 0.009 0.002 1.010 1.046
Drug use disorder HH 1.016 0.022 0.491 0.972 1.061
LL 0.960 0.017 0.016 0.928 0.992
Hepatitis HH 5.602 0.759 0.023 1.265 24.814
LL 0.808 0.746 0.774 0.187 3.483
HIV/AIDS HH 0.850 0.062 0.009 0.753 0.960
LL 2.061 0.116 <0.001 1.641 2.588
Hodgkin lymphoma HH 0.008 2.529 0.059 0.000 1.196
LL 48.361 2.204 0.078 0.644 3633.023
Hypertensive heart disease HH 1.214 0.038 <0.001 1.126 1.309
LL 1.034 0.036 0.361 0.963 1.109
Interstitial lung disease HH 1.218 0.095 0.037 1.012 1.466
LL 0.826 0.083 0.021 0.702 0.972
Leukemia HH 2.172 0.183 <0.001 1.518 3.106
LL 0.432 0.145 <0.001 0.325 0.573
LRI HH 0.943 0.012 <0.001 0.921 0.966
LL 1.047 0.012 <0.001 1.022 1.071
Mesothelioma HH 0.847 0.247 0.502 0.522 1.375
LL 1.954 0.280 0.017 1.130 3.380
Pancreatic HH 0.474 0.117 <0.001 0.377 0.596
LL 1.343 0.110 0.007 1.082 1.666
Peripheral vascular disease HH 1.034 0.179 0.851 0.729 1.468
LL 0.953 0.149 0.745 0.711 1.276
Tracheal, bronchus & lung HH 1.043 0.013 0.002 1.016 1.070
LL 0.967 0.010 0.001 0.947 0.986
Tuberculosis HH 0.094 1.068 0.027 0.012 0.761
LL 0.142 0.872 0.025 0.026 0.784

* Non-significant is considered as the reference category.

**ORs were calculated by taking exponent of coefficient for each covariate.